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Abstract
Background: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been shown to exert a synergistic
antitumor effect when combined with fluoropyrimidine. This synergy may be attributable to the downregulation of
thymidylate synthase (TS), which is frequently overexpressed in fluoropyrimidine-resistant cancer cells. However, the
molecular mechanism underlying the downregulation of TS has yet to be clearly elucidated.
Methodology and Principal Findings: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2
downregulates TS via inhibition of the nuclear translocation of EGFR and HER2. From our cDNA microarray experiments, we
determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this
was apparent in HER2-amplified cells. Targeted and pharmacologic inhibition assays confirmed that the dual inhibition of
EGFR and HER2 is required for the more effective reduction of TS as compared to what was observed with gefitinib or
trasutuzumab alone. Additionally, we determined that co-transfected EGFR and HER2 activate the TS gene promoter more
profoundly than do either EGFR or HER2 alone. The translocation of EGFR and HER2 into the nucleus and the subsequent
activation of the TS promoter were inhibited by lapatinib.
Conclusions and Significance: These results demonstrate that lapatinib inhibits the nuclear translocation of EGFR and HER2
and downregulates TS, thus sensitizing cancer cells to fluoropyrimidine.
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Introduction
Lapatinib (GW572016, Tykerb) is a dual synthetic reversible
inhibitor of EGFR and HER2 tyrosine kinases, and has been
demonstrated to inhibit significantly the proliferation of cancer
cells evidencing EGFR and/or HER2 overexpression both in vitro
and in vivo [1–3]. At the intracellular level, lapatinib binds
reversibly to the cytoplasmic ATP-binding site of the kinase,
thereby preventing receptor phosphorylation [1,4]. Lapatinib
blocks ligand-activated signaling from multiple receptor combina-
tions, including homo-and heterodimers of EGFR and HER2 [5];
preclinically, it inhibits the proliferation of trastuaumab-resistant
cancer cells [2,6]. Moreover, in contrast to trastuzumab, lapatinib
can inhibit HER2 activation via ligand-induced heterodimeriza-
tion or truncated HER2 receptors, and it has also proven effective
in the treatment of PTEN-deficient breast cancer, thus illustrating
the potential advantages of lapatinib over trastuzumab [7,8].
Recently, lapatinib has been shown to exert beneficial effects in
combination with capecitabine in patients with HER2-positive
advanced breast cancer that has progressed after prior treatment
with an anthracycline, a taxane, and trastuzumab [9]. In this trial,
the time to progression of patients treated with lapatinib and
capecitabine was prolonged significantly as compared to what was
observed in patients treated solely with capecitabine (8.4 months
vs. 4.4 months, p,0.001), which suggests that lapatinib may
overcome trastuzumab resistance. However, another possible
explanation for this observed synergistic effect would be that
lapatinib may enhance sensitivity to capecitabine. In this regard,
several lines of inquiry have demonstrated that EGFR-TKIs
inhibited the expression of the transcription factor E2F-1, thereby
inducing the downregulation of TS expression and activity, and
mediating the synergistic interaction with 5-FU [10,11]. However,
the molecular mechanism underlying the downregulation of TS
remains to be clearly elucidated. Fluoropyrimidines such as 5-FU
are extensively utilized in the treatment of colorectal, breast, and
aerodigestive tract cancers, and are intracellularly converted to 5-
fluoro- deoxyuridine-monophosphate (FdUMP), thus forming a
stable tertiary complex and inhibiting TS [12–14]. The results of
several studies have demonstrated that the expression of TS
functions as a key determinant of fluorpyrimidine sensitivity, and
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5933preclinical in vitro and in vivo studies have elucidated an inverse
relationship between TS expression in cancer cells and fluoropyr-
imidine sensitivity [15–18]. Thus, EGFR TKI may represent a
novel therapeutic strategy which can attenuate TS expression in
cancer cells.
EGFR and HER2 are cell surface receptors which transduce
mitogenic signals within the cells [19,20]. However, the nuclear
importation of EGFR and HER2 has been also demonstrated,
although its biological significance remains unclear. EGFR has
been detected in the nuclei of cancer cells and in primary tumor
specimens of various origins, as well as in those of other highly
proliferative tissues. While localized in the nucleus, EGFR may
operate as a transcriptional regulator. It has been previously
reported that nuclear EGFR regulates the expression of cyclin D1,
inducible nitric oxide synthase (iNOS), and B-MYB genes via
transactivational activity [21–23]. Furthermore, nuclear EGFR
has been demonstrated to interact physically with signal
transducer and activator of transcription 3 (Stat3) and E2F-1
[23,24]. Aside from EGFR, other receptors in the EGFR family,
including HER2, have also been detected within the nucleus
[25,26], but the biological significance of these receptors will
require additional study.
In this study, we attempted to determine the manner in which
lapatinib renders cancer cells susceptible to fluoropyrimidine. We
determined that EGFR and HER2 existed within the nucleus, and
that nuclear EGFR and HER2 bind to and activate the TS gene
promoter. We further noted that lapatinib inhibits the nuclear
translocation of EGFR and HER2, thereby induing a reduced
association with the TS promoter. The lapatinib-mediated
downregulation of TS was apparent in HER2-amplified cells;
however, it was also noticeable in the wild-type cells. It is also
important to note that the dual inhibition of EGFR and HER2 is
the most effective method for achieving maximal TS downregu-
lation. Taken together, these data show that lapatinib, a dual
inhibitor of EGFR and HER2 TS, may prove useful not only as a
targeted therapy, but also as a chemosensitizer of cytotoxic
anticancer drugs in a specific subset of tumors.
Results
Lapatinib downregulates fluoropyrimidine-target genes
including TS
Recently, we reported that lapatinib evidences significant
growth inhibitory activity in HER2-amplified gastric cancer
(GC) cells and, in combination with 5-FU, results in a synergistic
growth-inhibitory effect in vitro [27]. In the current study, these in
vitro findings were confirmed in an in vivo context, where it was
shown that lapatinib alone or a combination of lapatinib and 5-FU
potently inhibited the tumor growth of HER2-amplified N87 GC
cell-bearing xenografts (Fig. 1). These results further support the
rationale for a cancer therapy based on a combination of lapatinib
and fluoropyrimidine.
It has been previously demonstrated that EGFR TKI, such as
erlotinib/or gefitinib treatment with fluoropyrimidine, resulted in
an synergistic inhibitory effect in non-small-cell lung cancer cells,
possibly as the result of TS downregulation via the inhibition of
EGFR signaling [10,11]. Accordingly, we have speculated that
lapatinib may be superior to EGFR TKI from the standpoint of
chemosensitization to fluoropyrimidine. In order to address these
issues and investigate the underlying molecular mechanisms, we
first conducted a set of oligonucleotide microarray experiments to
compare the effects of gefitinib with lapatinib from the perspective
of the chemosensitization to fluoropyrimidine. We utilized three
different GC cell lines, SNU216 (EGFR
WT, HER2
Amp), which is
Figure 1. Combination of lapatinib and 5-FU potently inhibited tumor growth of N87-bearing xenografts. N87 cells (5610
6) were
injected s.c. into nude mice with randomization (n=6). Treatment with lapatinib (100 mg/kg, p.o., daily for 3 weeks) and 5-FU (50 mg/kg, i.p., once
weekly for 3 weeks) was initiated once the tumors had achieved a volume of 50–100 mm
3. Bars, SEM and repeated measures of ANOVA showed
statistically significant effects (P,0.005) in the lapatinib and combination groups.
doi:10.1371/journal.pone.0005933.g001
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SNU484 (EGFR
WT, HER2
WT) which is moderately sensitive to
lapatinib (IC50 m1 mM) and resistant to gefitnib (IC50.10 mM), or
SNU668 (EGFR
WT, HER2
WT, K-ras
MT) which is resistant to both
(lapatinib IC50.10 mM, gefitnib IC50.10 mM; Fig. 2A, left). The
expressions of representative nucleotide synthesis-related genes
[E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate
reductase), RRM2 (ribonucleotide reductase M2 polypeptide),
DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate
kinase 1)] were reduced as the result of gefitinib or lapatinib
treatment in TKI-sensitive cells. Fold reductions were decreased in
proportion with drug sensitivity in these cases. For example,
lapatinib downregulated gene expression in lapatinib-sensitive
SNU216 and SNU484 cells, but did not affect gene expression in
the lapatinib-resistant SNU668. As compared to gefitinib,
lapatinib treatment induced higher fold reductions of all of the
downregulated genes in SNU216 and SNU 484 cells (Fig. 2A,
right). Thus, it is probable that the inhibition of both EGFR and
HER2 appears to be more effective from the perspective of gene
regulation. It is also crucial to note that lapatinib modestly
downregulates gene expression in HER2 wild-type SNU484 cells,
as well as in HER2-amplified cells. The transcription factor E2F-1
downregulates nucleotide synthesis-associated genes, including TS,
and the change in E2F-1 as the result of lapatinib treatment was
apparent in SNU216 and SNU484 cells, but was not noted in the
SNU668 cells. All these data were confirmed via RT-PCR and
Western blotting (Fig. 2B). Lapatinib downregulated TS mRNA
and protein in a dose-dependent manner in the SNU216 and
SNU484 cells, but not in the SNU668 cells (Fig. 2B). In HER2-
amplified SNU216 cells that were sensitive to both, lapatinib
suppressed gene expression more potently than gefitinib. These
findings were confirmed in different HER2-amplified N87 and
SKBr3 cells following treatment with either gefitinib or lapatinib.
As is shown in Fig. 2C and Fig. S1, lapatinib consistently induced a
profound reduction of TS, TK1, DHFR, or RRM2 mRNA in a
dose-dependent manner as compared to gefitinib. Lapatinib
effectively inactivated phosphorylated-EGFR and -HER2 at the
same doses as used in Fig. 2C (Fig. 2D). Together, these results
revealed that lapatinib downregulates a variety of nucleotide
synthesis-related genes, including E2F-1 and TS. Moreover, the
gene modulation effect of the dual inhibitor is superior to that of
EGFR TKI, which is more apparent in HER2-amplified cells.
Considering that these nucleotide synthesis-related genes are
major determinants of fluoropyrimidine sensitivity, the dual
inhibition of EGFR and HER2 TK by lapatinib appears to
represent a promising strategy for the sensitization of cancer cells
to fluoropyrimidines in a subset of tumors.
Dual inhibition of EGFR and HER2 is required for TS
downregulation
In an effort to evaluate the biological and functional relevance
of the dual inhibition of EGFR and HER2, we assessed TS protein
levels following transfection with small interfering RNA (siRNA)
oligonucleotides directed against EGFR, HER2, or both in HER2-
amplified SNU216 and SKBr3, wild-type SNU484 cells (Fig. 3A).
The dual inhibition of EGFR and HER2 effectively abolished TS
expression in HER2-amplified SNU216, SKBr3, and N87 (data
not shown), and similar effects were also observed in the HER2
wild-type cells. Consistent with the results observed with TS
downregulation, co-transfection with EGFR and HER2 siRNA
induced a profound G1-arrest of cancer cells (Fig. 3B). These
results were confirmed by a pharmacological inhibitor experiment
showing that lapatinib significantly downregulated the TS protein
as compared with the effects of gefitinib or trastuzumab in SKBr3
cells (Fig. 3C). Thus, it can be concluded that the dual inhibition of
EGFR and HER2 is required for the more effective downregu-
lation of TS. Even in the HER2 wild-type cells, dual inhibition
appears to be superior to single inhibition from the perspective of
TS downregulation.
Lapatinib inhibits the nuclear translocation of EGFR and
HER2
While located in the nucleus, EGFR or HER2 has been shown to
function as a transcription factor for DNA repair and synthesis genes
[21]. In order to determine whether gefitinib or lapatinib influences
the nuclear localization of EGFR and HER2, we assessed the
cytoplasmic-to-nuclear distribution of EGFR and HER2 following
EGF stimulation. In HER2-amplified SNU 216, EGFR was
translocated into the nucleus with EGF-stimulation, and HER2
was stably detected both in the cytosol and nucleus. After lapatinib
treatment,both nuclear EGFR and HER2 weresignificantlyreduced
in these cells, whereas gefitinib treatment induced modest reduction
of nuclear EGFR. In contrast, cytosolic EGFR and HER2 were not
altered by either gefitinib or lapatinib (Fig. 4A). In the case of EGFR,
lapatinib appeared to inhibit the ligand-dependent translocation of
EGFR into the nucleus. However, as HER2 has already been
detected in the absence of ligand in HER2-amplified cells, lapatinib
may inhibit preexisting translocated nuclear HER2, independently of
the ligand. Although its molecular mechanism will require further
investigation, lapatinib appears to reduce levels of nuclear EGFR and
HER2, possibly via the inhibition of ligand-dependent or indepen-
dent translocation of EGFR and HER2.
Interaction of nuclear EGFR and HER2 with TS promoter
is inhibited by lapatinib
Wesubsequentlyassessed theeffectsofnuclear EGFR andHER2
on TS gene transcription. First, we compared TS promoter activity
according to the transfection of EGFR and HER2 nuclear
localization signal (NLS) WT or MT in both EGFR and HER2-
negative CHO cells. Following transient transfection with EGFR-
NLS WT, HER2-NLS WT or both, we noted that TS promoter
activity was increased to a greater degree by forced HER2
expression than by forced EGFR expression, and was activated
more profoundly by dual-expression than by single-expression. By
way of contrast, after transfection with EGFR-NLS MT, HER2-
NLS MT, or both, TS promoter activation was lower than the
effects of WT (Fig. 4B). Consistently, the knockdownof EGFR and/
or HER2 and lapatinib treatment significantly reduced the ability of
theTS promoter inresponse to EGFinSKBr3cells, ascompared to
what was observed with gefitinib or trastuzumab alone (Fig. 4C).
CHIP demonstrated that EGF-induced nuclear EGFR and HER2
bindtothe TSpromoterinSNU216and SKBr3cells,andthattheir
association was abolished by lapatinib (Fig. 4D). Collectively, these
results reveal that nuclear EGFR and HER2 activate TS gene
transcription via binding to the TS promoter, and that the TS
promoter-bound EGFR and HER2 are inhibited by lapatinib,
ultimately resulting in the downregulation of TS.
Discussion
In this study, we have demonstrated that lapatinib, a dual
inhibitor of EGFR and HER2 TK, effectively downregulates a
variety of nucleotide synthesis-related genes, including TS, and
exhibits activity superior to that of gefitinib not only in HER2-
amplified cells, but also in wild-type cells. As a mechanism, we
have determined, for the first time, that nuclear EGFR and HER2
activate TS gene transcription, and that EGFR and HER2-bound
TS promoter activities are inhibited by lapatinib treatment.
Lapatinib Downregulates TS
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or heterodimer and transduce the mitogenic signal into the nucleus
[21]. However, it has also been demonstrated that ligand-activated
EGFR or overexpressed HER2 can form a homo- or heterodimer,
and that these are also translocated into the nucleus. Therefore,
nuclear EGFR and/or HER2 can operate as transcription factors,
activating a variety of genes, including iNOS, B-MYB, and COX-2
[21–25]. Considering that nuclear EGFR and HER2 can function
as transcription factors, it can be plausibly surmised that other genes
involved in cell proliferation might also be regulated by nuclear
EGFR and HER2.In the currentstudy, we demonstratedthat TS is
activated by nuclear EGFR and HER2. In the context of TS
activation, it appears that EGFR and HER2 may perform a pivotal
role, as the dual inhibitor, lapatinib, or the double knockdown of
EGFR and HER2, evidenced the maximal TS inhibitory effects. It
is also worth noting that lapatinib is superior to gefitinib with regard
to gene regulation, which also emphasizing the significance of the
dual inhibition of EGFR and HER2.
In SNU216 cells evidencing HER2 overexpression, we
determined that nuclear EGFR and HER2 are induced in a
ligand-dependent and -independent fasion, respectively. The
nuclear translocation of EGFR upon ligand stimulation is
noticeable in these cells and is inhibited by lapatinib, which
implies that the inhibition of EGFR is also required in HER2-
amplified cells. It is also conceivable that nuclear EGFR and
HER2 may form a homo- and heterodimer, which would bind to
the promoters of target genes such as TS. We have previously
determined that lapatinib inhibits the heterodimer of EGFR and
HER2 in cancer cells [5]. Because lapatinib reduced the levels of
nuclear EGFR and HER2, we speculated that lapatinib might also
destabilize the levels of hetero- or homodimers of EGFR and
HER2 in the nucleus. In HER2 wild-type cells, lapatinib exerted
modest gene downregulation effects, as is shown in Figs. 2A and
2B. Therefore, it appears that lapatinib can be tested for the
purpose of gene modulation, regardless of the HER2 status.
Collectively, the data provided in this study demonstrate the
molecular mechanisms underlying the synergy between lapatinib
and fluoropyrimidine. In the future, lapatinib should be investi-
gated as a chemosensitizing agent that enhances cytotoxicity or
circumvents resistance against anticancer drugs, not only in
HER2-amplified, but also in HER2 wild-type tumors.
Materials and Methods
Reagents
Gefitinib was kindly provided by AstraZeneca, and lapatinib
was generously provided by GlaxoSmithKline. Trastuzumab was
kindly provided by Roche. 5-FU was obtained from Choong Woe
(Seoul, Korea). Epidermal growth factor (EGF) was purchased
from Sigma-Aldrich (St. Louis, MO).
Cell Culture
Four human gastric cancer cells (SNU216, SNU484, SNU668,
N87), human breast cancer cells (SKBr3), and Chinese hamster
ovary cells were grown at 37uCunder 5% CO2 in RPMI-1640 or
DMED culture media containing 10% fetal bovine serum
(WELGENE Inc., Korea). The mycoplasma free cells were
purchased from the Korean Cell Line Bank (Seoul, Korea,
ref[28]) or the American Type Culture Collection.
N87 Xenografts
All animal experiments were approved by the Institutie
Laboratory Animal Resources Seoul National University and
Use Committee. Six-to-eight-week-old female BALB/c athymic
(nu+/nu+) mice were purchased from Central Lab Animal Inc.
(Seoul, Korea). The initial body weight of the animals at the time
of arrival was between 18 and 20 g. Mice were allowed to
acclimatize to local conditions for 1 week before being injected
with cancer cells. Tumors were induced by injecting H1975 cells
(5610
6) subcutaneously into the right flank of mice. The tumors
were then measured twice a week using calipers, and the tumor
volume in mm
3 was calculated according to following formula:
{(width)
26(height))/2}. When tumors had reached a volume of
50–100 mm
3, treatment with either lapatinib, 5-FU, a combina-
tion of lapatinib and 5-FU, or a vehicle control was initiated.
Lapatinib were administered via oral gavage at a concentration of
100 mg/kg in 0.5% (W/W) hydroxypropylmethylcellulose
(HPMC) with 0.1% (W/W) Tween80 (Sigma) in sterile milli-Q
water Monday through Friday for 3 weeks. A dose of 50 mg/kg of
5-FU was given intraperitoneally once weekly for 3 weeks.
Statistical analysis to compare tumor sizes in xenograft-bearing
mice was performed with ANOVA. Differences between groups
were considered statistically significant if P,0.05.
cDNA Microarray
SNU216, SNU484, and SNU668 cells were grown for 24 hours
in the presence of gefitinib (1 mmol/L) or lapatinib (1 mmol/L),
after which they were lysed. The total RNA was then processed
and hybridized to an Affymetrix Genechip HG-U133 set
(Affymetrix, Santa Clara, CA) via a DNA link (Seoul, Korea)
according to the manufacturer’s protocols. All samples were
analyzed and reported according to MIAME guidelines. The
GeneExpress Software System Fold Change Analysis tool was used
to identify all present genes expressed at least 2-fold greater in the
drug-treated cells compared with DMSO-treated cells. For each
gene fragment, the ratio of the geometric means of the expression
intensities in DMSO treated cells and the drug treated cells cells
was calculated, and the fold change was then calculated on a per
fragment basis. Confidence limits were calculated using a two-
sided Welch modified t test on the difference of the means of the
logs of the intensities.
Reverse Transcription-PCR and Real-Time PCR Analysis
Specific mRNAs were semiquantitated via reverse transcription
(RT-PCR) or real-time PCR with the iCycler IQ detection system
(Bio-Rad Laboratories, Hercules, CA) using SYBR green I
(Molecular Probe, Eugene, OR) in triplicate reactions. The
primers used in the PCR reaction were as follow: E2F1, forward
primer59- ACGCTATGAAACCTCACTAAA-39 and reverse
Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. A, Downregulated fluoropyrimidine-sensitivity genes by oligonucleotide
microarray based on analysis comparing DMSO/lapatinib-treatment versus DMSO/gefitinib-treatment samples at 24 hours of each treatment in
SNU216, SNU484, or SNU668 cells. B, The indicated cells were treated with lapatinib (0.1, 1, 1 mmol/L) for 24 hours. mRNA levels of E2F1 and TS were
assessed via RT-PCR (upper). b-Actin was utilized as a loading control. Western blots are provided for E2F1 and TS (lower). a-tubulin was employed as a
loading control. C and D, N87, and SKBr3 cells were grown for 24 hours in the presence of gefitinib (0.01, 0.1, 1 mmol/L) or lapatinib (0.01, 0.1, 1 mmol/
L). Western blots are shown for phosphorylated and total EGFR, and HER2. mRNA levels of TS, TK1, DHFR, and RRM2 were determined via quantitative
real-time RT-PCR. Columns, means; bars, 6SD. *, P,0.05; **, P,0.05;***, P,0.05, gefitinib versus lapatinib at 0.01, 0.1, and 1 mmol/L doses. The
expressed data are representative of three independent experiments.
doi:10.1371/journal.pone.0005933.g002
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er 59- TCTGGAAGGGTGTTTTGGA-39 and reverse primer 59-
CCTCCACTGGAAGCCATAAA-39, TK1, forward primer 59-
CAGCTTCTGCACACATGAC-39 and reverse primer 59-AGTG-
CAGCCACAATTACGG-39, DHFR, forward primer 59- TCC-
ATTCCTGAGAAGAATCGACCTT-39 and reverse primer 59-
CACAAATAGTTTAAGATGGCCTGGG-39, RRM2, forward
primer 59-GTGGAGCGATTTAGCCAAGA-39and reverse primer
59-TGACCTCTTTGTCCCCAATC-39,D U T ,f o r w a r dp r i m e r5 9-
CCCTTCTGGGTGTTATGGGAAGA-39 and reverse primer 59-
CCAGCTCCTACATCAATAAAGTGTTT-39, NME1, forward
primer59-TTCACCCTGAGGAACTGGTAGATT-39andreverse
primer 59-GTGGTCTGCCCTCCTGTCA-39,A C T I N ,f o r w a r d
primer 59- AGAGCTACGAGCTGCCTGAC and reverse primer
59- GGATGCCACAGGACTCCA-39.
Antibodies and Western Blotting
Antibodies against E2F-1, a-tubulin, and Lamin B were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). p-
EGFR (pY1068), EGFR, p-HER2 (pY1221/1222), HER2, and
TS antibody was acquired from Cell Signaling Technology
(Beverley, MA), or NeoMarkers (Fremont, CA). Cultured cells
that had reached ,70% to 80% confluence were used for protein
analyses. The cells were treatmented with different conditions as
described. The cells were lysed in RIPA buffer on ice for 15 min
(50 mmol/L Tris-HCl pH 7.5, 1% NP-40, 0.1% Na deoxycho-
late, 150 mmol/L NaCl, 50 mmol/L NaF, 1 mmol/L sodium
pyrophosphate, 1 mmol/L sodium vanadate, 1 mmol/L nitro-
phenolphosphate, 1 mmol/L benzamidine, 0.1 mmol/L PMSF,
0.1 mmol/L aprotinin, 0.1 mmol/L leupeptin, 0.1 mmol/L
pepstatin A) and centrifuged at 13,000 rpm for 20 min. Samples
containing equal amount of total protein were resolved in SDS-
polyacrylamide denaturing gel, transferred to nitrocellulose
membranes, and probed with antibodies. Detection was per-
formed using an enhanced chemiluminescence system (Amersham
Pharmacia Biotech).
Cell Cycle Analysis
Cells were washed twice in phosphate buffered solution (PBS),
fixed in 70% ethanol, and stored at 220uC until required for
analysis. Before analysis, cell suspensions were washed with PBS,
and digested with RNase A (50 mg/ml) for 15 minutes at 37uC and
then stained with propidium iodide (50 mg/ml). Cell DNA
contents (10,000 cells/experimental group) were determined using
a FACSCalibur flow cytometer (Becton Dickinson Biosciences,
San Jose, CA) equipped with a ModFit LT program (Verity
Software House Inc.), as previously described [29].
Nuclear Fractionation
SNU216, SKBr3, and N87 were serum-starved for 24 h and
stimulated with EGF (100 ng/ml) for 30 min and then collected
for lysis. Nuclear fractions were prepared using NE-PER
extraction reagents (Pierce Chemical, Rockford, IL), according
to the manufacturer’s instructions. Briefly, after removal of the
cytoplasmic fraction using cytoplasmic extraction reagents, the
insoluble pellet obtained was resuspended in nuclear extraction
reagent (100 mmol/L KCl, 10 mmol/L HEPES, pH 7.9, 10%
glycerol, 1 mmol/L dithiothreitol, 5 mmol/L MgCl2, 0.1% NP-
40, and 10 mmol/L NaF) containing protease inhibitors. After
vigorously vortexing every 10 min during incubation on ice for
40 min, the nuclear fraction was isolated by centrifugation.
Westernblotting for Lamin B and a-tubulin was performed to
confirm the nuclear fraction and to exclude cytoplasmic
contamination, respectively.
EGFR and HER2-NLS Mutant Constructs
EGFR-NLS MT (645-47, RRR.AAA) and HER2-NLS MT
(667-68, RR.GG) were induced in the cDNA using a Quick-
ChangeTM Site-directed mutagenesis kit (Stratagene, La Jolla,
CA), according to the manufacturer’s protocol, as previously
described [30,31].
Luciferase Reporter Assay
After cotransfection with pGL3-TS-Luc and EGFR or HER2
plasmids, the cells were lysed and the TS-luciferase activity was
evaluated using a TR717 microplate luminometer (Applied
Biosystems, Foster City, CA), in accordance with the manufac-
turer’s instructions. The human TS promoter region was designed
as previously described [32]. pCMV-b-Gal was also transfected in
order to normalize the transfection efficiencies.
Chromatin Immunoprecipitation Assay (CHIP)
SNU216 and SKBr3 were serum-starved for 24 h and
stimulated with EGF (100 ng/ml) for 30 min. Briefly, cells were
cross-linked by addition of 1% formaldehyde for 10 min and
glycine was added (125 mmol/L final) for 5 min to stop the cross-
linking reaction. Cells were then lysed with a lysis buffer and
sonicated. One-tenth of the total chromatin lysate was used for
purification of total genomic DNA. The rest of the lysate was used
for immunoprecipitation with EGFR or HER2 antibody. After the
collection of immunoprecipitates using protein G agarose, protein-
DNA complexes were eluted and heated at 65uC to reverse cross-
linking. After digesting proteins by proteinase K, DNA fragments
were purified using the QIAquick PCR purification kit (QIAGEN,
Valencia, CA). Either total or immunoprecipitated DNA were
analyzed by PCR of 30 or 35 cycles, respectively, at 94uC for 30 s,
56uC for 30 s, and 72uC for 1 min. Specific sequences of the TS
promoter in the immunoprecipitates were detected by PCR with
primer: forward, 59- TGGCGCACGCTCTCTAGAGC-39 and
reverse, 59- GACGGAGGCAGGCCAAGTG-39. SNU216 and
SKBr3 were serum-starved for 24 h and stimulated for 30 min
with EGF (100 ng/ml). The primer utilized for the CHIP assay
harbors TS essential promoter regions and E2F-1 binding sites
[22,33].
Statistics
The statistical significance of the results was calculated by
unpaired Student’s t test, and P values of ,0.05 were considered
to be statistically significant.
Figure 3. Dual inhibition of EGFR and HER2 kinase activity is required for TS downregulation. A, SiRNAs targeting endogenous EGFR,
HER2, and both missense transcripts were transfected with SNU216, SKBr3, and SNU484 prior to 48 hours of lysate treatment. Whole cell extracts
were Western-blotted with EGFR, HER2, and TS. a-tubulin was utilized as a loading control. B, The cells were fixed with 70% ethanol, stained with
propidium iodide, and subjected to flow cytometric analysis. Proportions of cells in the G1, S, and G2-M phase were quantified using the ModFit LT
program (Verity Software House Inc.); total percentages of G1, S, and G2-M phases are 100% in our data. C, SKBr3 cells were exposed for 24 h to
gefitinib (1 mmol/L), trastuzumab (100 ng/ml), or lapatinib (1 mmol/L). Western blots are provided for TS. a-tubulin was used as a loading control. The
expressed data are representative of three independent experiments.
doi:10.1371/journal.pone.0005933.g003
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Figure 4. TS gene transcription by nuclear EGFR and HER2 is inhibited by lapatinib. A, Prior to harvesting, SNU216 cells were serum-
starved for 24 hours, then grown for 3 h in the presence of gefitinib and lapatinib (0.1, 1 mmol/L), followed by 30 minutes of EGF (100 ng/mL)
stimulation, then subjected to biochemical fractionation to separate the nucleus from the cytosolic material. Western blots are shown for EGFR and
HER2. The loading controls were Laminin B (nucleus marker) and a-tubulin (cytosol marker). B, EGFR- and HER2-negative CHO cells were co-
transfected with TS-promoter luciferase construct and plasmids encoding for EGFR-NLS WT/MT, HER2-NLS WT/MT, or both, in addition to mock
plasmid. Following 24 hours of serum-starvation, the cells were stimulated for 6 hours with EGF and subjected to luciferase assays. C, TS-promoter
luciferase construct and Si-RNAs targeting endogenous EGFR, HER2, and both missense transcripts were transfected with SKBr3, prior to 48 hours of
lysate treatment (left). The cells transfected with TS-promoter luciferase construct were pretreated with gefitinib (1 mmol/L), trastuzumab (100 ng/ml),
or lapatinib (1 mmol/L) for 24 hours (right). Luciferase activity was then determined. Columns, means; bars, 6SD. D, SNU216 and SKBr3 cells were
serum-starved for 24 hours, then grown in the presence of lapatinib (1 mmol/L) for 3 hours, followed by 30 minutes of EGF (100 ng/mL) stimulation,
and then subjected to CHIP analysis. Immunoprecipitation was then conducted with anti-EGFR, anti-HER2, or normal rabbit IgG. The TS promoter
region which contained essential promoter regions and E2F-1 binding sites was PCR-amplified. Input nuclear DNA were utilized as a PCR control. The
expressed data are representative of three independent experiments.
doi:10.1371/journal.pone.0005933.g004
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